XML 37 R27.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables) | 3 Months Ended
--- | ---
Sep. 30, 2022
Notes Tables |
Schedule of the Consolidated Changes in Equity | Consolidated Changes in Equity (amounts in thousands) ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Bio-Techne Shareholders |  | ​ | ​ |  |  | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Common Stock | ​ | Paid-in | ​ | Retained | ​ | Comprehensive | ​ | Noncontrolling | ​ | ​ | ​
​ | ​ | Shares | ​ | Amount | ​ | Capital | ​ | Earnings | ​ | Income(Loss) | ​ | Interest | ​ | Total
Balances at June 30, 2022 |  | 39,160 | ​ | ​ | 392 | ​ | ​ | 653,657 | ​ | ​ | 1,122,921 | ​ | ​ | (75,200) | ​ | ​ | (759) | ​ | ​ | 1,701,011
Net earnings |  | - | ​ | ​ | - | ​ |  | - | ​ |  | 89,555 | ​ |  | - | ​ |  | 179 | ​ |  | 89,734
Other comprehensive loss |  | - | ​ | ​ | - | ​ |  | - | ​ |  | - | ​ |  | (16,762) | ​ |  | 0 | ​ |  | (16,762)
Reclassification of cumulative translation adjustment for Eminence to non-operating income | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | 152 | ​ | ​ | (33) | ​ | ​ | 119
Elimination of noncontrolling equity interest from sale of Eminence |  | - | ​ |  | - | ​ |  | - | ​ |  | - | ​ |  | - | ​ |  | 613 | ​ |  | 613
Share repurchases |  | (55) | ​ |  | (1) | ​ |  | - | ​ |  | (19,561) | ​ |  | - | ​ |  | - | ​ |  | (19,562)
Common stock issued for exercise of options |  | 107 | ​ |  | 1 | ​ |  | 9,422 | ​ |  | (11,428) | ​ |  | - | ​ |  | - | ​ |  | (2,005)
Common stock issued for restricted stock awards |  | 11 | ​ | ​ | - | ​ |  | - | ​ |  | (6,427) | ​ |  | - | ​ |  | - | ​ |  | (6,427)
Cash dividends |  | - | ​ | ​ | - | ​ |  | - | ​ |  | (12,545) | ​ |  | - | ​ |  | - | ​ |  | (12,545)
Stock-based compensation expense |  | - | ​ |  | - | ​ |  | 14,364 | ​ |  | - | ​ |  | - | ​ |  | - | ​ |  | 14,364
Common stock issued to employee stock purchase plan |  | 9 | ​ | ​ | - | ​ |  | 2,517 | ​ |  | - | ​ |  | - | ​ |  | - | ​ |  | 2,517
Employee stock purchase plan expense | ​ | - | ​ | ​ | - | ​ | ​ | 97 | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | 97
Balances at September 30, 2022 |  | 39,232 | ​ | $ | 392 | ​ | $ | 680,057 | ​ | $ | 1,162,515 | ​ | $ | (91,810) | ​ | $ | - | ​ | $ | 1,751,154
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Bio-Techne Shareholders |  | ​ | ​ |  |  | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Common Stock | ​ | Paid-in | ​ | Retained | ​ | Comprehensive | ​ | Noncontrolling | ​ | ​ | ​
​ | ​ | Shares | ​ | Amount | ​ | Capital | ​ | Earnings | ​ | Income(Loss) | ​ | Interest | ​ | Total
Balances at June 30, 2021 |  | 38,955 | ​ | $ | 390 | ​ | $ | 534,411 | ​ | $ | 1,085,461 | ​ | $ | (57,291) | ​ | $ | 8,263 | ​ | $ | 1,571,234
Net earnings | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 69,615 | ​ | ​ | ​ | ​ | ​ | (634) | ​ | ​ | 68,981
Other comprehensive income (loss) |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  |  | ​ |  | (6,925) | ​ |  | (39) | ​ |  | (6,964)
Common stock issued for exercise of options |  | 295 | ​ |  | 3 | ​ |  | 36,345 | ​ |  | (13,481) | ​ |  |  | ​ |  |  | ​ |  | 22,867
Common stock issued for restricted stock awards |  | 20 | ​ |  | 0 | ​ |  | 0 | ​ |  | (9,765) | ​ |  |  | ​ |  |  | ​ |  | (9,765)
Cash dividends |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  | (12,493) | ​ |  | ​ | ​ |  |  | ​ |  | (12,493)
Stock-based compensation expense |  | ​ | ​ | ​ | ​ | ​ |  | 11,396 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 11,396
Common stock issued to employee stock purchase plan |  | 3 | ​ |  | 0 | ​ |  | 1,358 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 1,358
Employee stock purchase plan expense |  | ​ | ​ | ​ | ​ | ​ |  | 341 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 341
Balances at September 30, 2021 |  | 39,273 | ​ | $ | 393 | ​ | $ | 583,851 | ​ | $ | 1,119,337 | ​ | $ | (64,216) | ​ | $ | 7,590 | ​ | $ | 1,646,955
Schedule of each component of other comprehensive income (loss) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Unrealized | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Gains | ​ | Foreign | ​ | ​ | ​
​ | ​ | (Losses) on | ​ | Currency | ​ | ​ | ​
​ | ​ | Derivative | ​ | Translation | ​ | ​ | ​
​ |  | Instruments |  | Adjustments |  | Total
Balance as of June 30, 2022 | ​ | $ | 8,069 | ​ | $ | (83,269) | ​ | $ | (75,200)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne | ​ |  | 4,376 | ​ |  | (21,457) | ​ |  | (17,081)
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1) | ​ |  | 319 | ​ | ​ | ​ | ​ | ​ | 319
Reclassification of cumulative translation adjustment for Eminence to non-operating income, net of taxes, attributable to Bio-Techne | ​ | ​ | — | ​ | ​ | 152 | ​ | ​ | 152
Balance as of September 30, 2022(2) | ​ | $ | 12,764 | ​ | $ | (104,574) | ​ | $ | (91,810)
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Unrealized | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Gains | ​ | Foreign | ​ | ​ | ​
​ | ​ | (Losses) on | ​ | Currency | ​ | ​ | ​
​ | ​ | Derivative | ​ | Translation | ​ | ​ | ​
​ |  | Instruments |  | Adjustments |  | Total
Balance as of June 30, 2021 attributable to Bio-Techne | ​ | $ | (6,193) | ​ | $ | (51,098) | ​ | $ | (57,291)
Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne | ​ |  | 84 | ​ |  | (8,607) | ​ |  | (8,523)
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1) | ​ |  | 1,598 | ​ |  | — | ​ |  | 1,598
Balance as of September 30, 2021 (2) | ​ | $ | (4,511) | ​ | $ | (59,705) | ​ | $ | (64,216)
​
| (1) | Gains (losses) on the interest swap are reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified ($417) to interest expense and recorded a related tax benefit of $98 during the quarter ended September 30, 2022. The Company reclassified ($2,091) to interest expense and a related tax benefit of $493 during the quarter ended September 30, 2021.
​
| (2) | The Company had a net deferred tax liability of $3,921 and a net deferred tax benefit of $1,391 included in the accumulated other comprehensive income loss as of September 30, 2022 and 2021, respectively.

X
- Definition Tabular disclosure of the components of accumulated other comprehensive income (loss). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900 + Details
Name: | us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration